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A B S T R A C T
Objective: Although the global rate of multiple sclerosis (MS) is low, a few studies have docu-
mentedhighcosts. Costs arehighlyvariabledependingonMSstage.This studywasdesigned to
assess the economic burden ofMedicare-eligible patients byMS type in theUnited States using
a claims-based classification algorithm to examine cost variation by disease stage.
Methods: A sample of 2003 to 2006Medicare patients was selected. Cases were classified as
pre-existing progressive MS or pre-existing relapsing-remitting MS (RRMS); the latter were
further subdivided into relapsing, remitting, or stable.
Results: The sample had 5044 MS subjects, of whom 34.4% had prevalent progressive MS
and 65.6% had prevalent RRMS. There were many chronic, comorbid conditions. The
mean all-cause Medicare expenditures (not including self-administered medications)
per person-year for MS in 2006 were $23,630 for prevalent progressive patients and $5887
for prevalent RRMS patients. Within the RRMS type, Medicare expenditures per person
per month in 2006 were $1418 for relapsing patients, $608 for remitting patients, and
$331 for stable patients.
Conclusions: There are substantial cost advantages to Medicare for keeping RRMS patients
in a stable health state and in keeping them from advancing in disability severity. The
overall cost advantage would be diminished by the large cost burden of comorbidity, which
would likely remain fixed with improved MS therapies.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research(ISPOR). Published by Elsevier Inc.
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ultiple sclerosis (MS) is recognized as a relatively rare con-
ition with an estimated 2008 prevalence in the United States
f 135 per 100,000 persons [1] and an incidence of 4.0 new
ases per 100,000 [1,2]. Alongwith northern Europe, theUnited
tates has the highestMS rates in theworld, and the condition
Funding: The sponsor of this research project is Wyeth Researc
rs and received compensation from Wyeth to conduct this anal
esearch, which funded the study.
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E-mail: dmg@jen.com.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.oi:10.1016/j.jval.2010.10.022as proved costly. US total annual direct medical costs per
atient were estimated to be $12,879 in 2004, with 65% of that
mount attributed to prescription medications, 26% to outpa-
ient care, and 8% to inpatient care [3]. In this study, patients
eceiving disease-modifying drugs had annual costs of ap-
roximately $14,000 more than other MS patients.
A slightly earlier study estimated that mean annual costs
anged from $9500 to $10,200 per patient (cost year is not evi-
n Gilden and Joanna Kubisiak are independent contract research-
f Medicare patients. Arthur Zbrozek was an employee of Wyeth
5 Bigelow Street, Cambridge, MA 02139, USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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62 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 1 - 6 9ent), with medications representing the greatest amount at
7300 to $8100 [4]. A still earlier study, conducted before the
idespread availability of disease-modifying drugs, reported
hat the annual direct medical costs were $13,048 (1997) for
edicare patients, $11,331 (1991–1996) for disabled Medicaid
atients, and $7677 (1995) for privately insured patients [5].
hese costs were two to three times the mean costs for
on-MS beneficiaries.
Remarkably, this last study noted that 5% of the privately
nsured MS patients accounted for almost half of all MS costs
ncurred in this population. This result was an early sign of the
elationship betweenMS disease severity and cost, a discussion
hat continues to this day [6]. It appears that disease severity
orrelates with increased care cost, which is quite plausible.
here is, however, no consensus method for determining dis-
bility in this disease, whose course varies widely from indi-
idual to individual. In an attempt to produce a reliable scor-
ng system, the Genetic Analysis of Multiple Sclerosis in
uropeans (GAMES) consortium created theMultiple Sclerosis
everity Score (MSSS) [7]. The MSSS relates the commonly
sed Expanded Disability Status Scale (EDSS) with MS dura-
ion to create a more reliable measure of disease status. This
S-specific grading system can measure the rate of MS pro-
ression, including the effect of drug treatment [8]. In addition
o medical outcome studies, it might find application in strat-
fying patients when investigating care costs.
The introduction of more expensive disease-modifying
rugs hasmeant that even patients with early, slow-progress-
ng MS (relapsing-remitting MS [RMSS]) have become a high-
ost population [6,9]. At the same time, cost-of-illness studies
isk underplaying the economic burden ofmore advanced dis-
ase. These studies frequently depend on insurance or health
ystem claims databases, which do not include indirect med-
cal costs or any nonmedical expenditures. Unrecorded
harges, already large in less severe disease, grow dispropor-
ionately as MS disability advances, according to EDSS assess-
ent [6,9,10].
The alternative to analyzing medical claims databases has
een to survey patients found in MS support group lists or
egistries. The most thorough study in the United States, Ko-
elt et al. [11,12], collected information on disease severity/
isability from patients taking part in the North American Re-
earch Committee on Multiple Sclerosis (NARCOMS) Global
atient Registry. The authors mailed a questionnaire to a ran-
om subsample of 4000 persons and received 1901 usable re-
ponses. Almost all respondents (94%) were receiving a dis-
ase-modifying drug.
The authors found that 2004 indirect costs for MS patients
mounted to 47% of total charges. Among these items were
arly retirement (29.0% of total costs), informal care (9.8% of
otal costs), and lost work time or income (7.1%) [11,12]. Drugs
ade up 39.5% of total costs. Informal care amounted to only
.9% of total costs for MS patients with mild disability; they
rew to 20.4% in severely disabled patients. Byway of compar-
son, a survey conducted in 1994, before the era of disease-
odifying drugs, reported that informal care constituted
3.7% of total annual expenditures [13].
Cost-of-illness studies have been heavily criticized be-ause of wide variation in their results, an issue that encom- fasses MS and other diseases [6,14]. Several factors under-
ine confidence in these studies. In addition to the lack of
ndirect costs, the medical cost of comorbidities is also fre-
uently missing. Surveys results are weakened by the self-
eport nature of the responses. Sampling bias is a problem for
oth survey- and claim-based studies: patients with either
ild or severe disease may be omitted. It is noteworthy that
atients are receiving MS diagnoses earlier in the course of
isease, making it hard to compare the results of older and
ewer studies [15].
Future therapies developed for one ormore types ofMSwill
enefit from enhanced understanding of economic outcome
atterns. In this report we expand the comprehension of eco-
omic burden through the study of MS patients classified by
iagnostic stage rather than by disease severity. We selected
ases reimbursed by Medicare, the largest reimbursement
gent of MS patients in the United States. It covers approxi-
ately one-third of all cases. Stratifying patients in the data-
ase according to disease stage (RRMS vs. progressive disease)
s an innovation that requires carefully elucidated algorithms.
ur results support more accurate modeling of the savings
erived from introducing new expensive therapies. They sug-
est how to factor into such models the extent to which the
ew drugs delay or ameliorate MS’s natural course of disease
nd the attendant costs of care.
ethods
tudy period and study population
he study data were extracted from the US national Medicare
% sample for the years 2003 through 2006. The Medicare 5%
ample is a replenishing panel population produced and
aintained annually by the Centers for Medicare and Medic-
id Services (CMS). A beneficiary is selected into the panel
ased on the last two digits of his or her Medicare account
umber and remains in the sample until a change in the ac-
ount number (rare) or death. Full Medicare claims and enroll-
ent histories for each panel member are included in the
atabase. Beneficiaries with a diagnosis code for MS of
CD9-CM 340 were identified, and the date of the first report of
diagnosis of MS from 2003 to 2006 was used as the index
ate. The following restrictions were applied to obtain the fi-
al study cohort: 1) a primary physician or hospital MS diag-
osis in 2006; 2) continuous Medicare eligibility from the first
bserved Medicare eligible month through the last observed
ligible month between 2003 and 2006; and 3) Medicare fee-
or-service eligibility consisting of Medicare Parts A and B
ithout Medicare HMO participation in the first month. Ben-
ficiaries notmeeting the study criteriawould not beMedicare
ee-for-service eligible and/or have complete and continuous
ligibility over the study period. In the excluded cases, it
ould not be possible to observe the complete diagnostic and
tilization histories for these individuals. Estimated from the
% data, 163,840 Medicare beneficiaries had an MS diagnosis
n 2006. Of those, 124,560 (76%) met the above criteria. Quali-
ying MS beneficiaries were classified by their disease mod-
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63V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 1 - 6 9led status in 2006, and 2006 served as the measurement year
or all analyses.
The Medicare program enrolls virtually all US elderly and
ounger adults with a qualifying severe disability. US Medi-
are eligibility for the disabled begins 2 years after the Social
ecurity Administration determines that the person is com-
letely disabled. The Medicare data do not record the qualify-
ng disability type; however, the presence of an MS diagnosis
t time of Medicare enrollment is highly indicative of MS as
he cause. Those younger than 65 years of age in the Medicare
S population will probably be more impaired (i.e., with sec-
ndary progressive MS) than the total MS population because
he former are at least 2 years past being completely disabled
y the disease. On the other hand, the elderly Medicare MS
opulation constitutes a complete sample of all elderly MS
atients at various stages of disease progression.
lassifying patients by MS type
atients were categorized according to whether they were prev-
lent or incident cases in 2006. Prevalent (pre-existing) caseshad
diagnosis code of MS prior to 2006 and at least 3 months of
edicare fee-for-service eligibility prior to their index month.
ncident cases were those with at least 3 months of Medicare
ee-for-service eligibility prior to their index month and whose
rst diagnosis of MS in 2006 was their index month. Cases with
ess than 3months ofMedicare fee-for-service eligibility prior to
heir index date in 2006 were not included in an analytic cohort.
f all the caseswithMS thatwere classified, 81%were prevalent
ases and 6% were undetermined and excluded. Thirteen per-
ent of the cases in the 5% sample (796) were incident; these
ere examined and then ignored because theywere not directly
elated to the study’s objectives.
Prevalent MS cases required further stratification as either
RMS or progressiveMS, but diagnostic codes and other direct
ndicators in the Medicare data do not distinguish between
hese twodisease categories.Weused the patterns of support-
ve care that appeared in individual patient claims records to
arse the population. The underlying concept is that progres-
ive MS has a pattern of care that is stable or escalates over
ime. RRMS is characterized by episodes of supportive care
nterrupted by periods of decreased or no care.
We therefore categorized each month according to the
ighest level of supportive therapy that was received. Sup-
ortive therapies received a rank according to the following
ierarchical order: 1) nursing home; 2) home health; 3) se-
ected rehabilitation therapy/durable medical equipment
DME); and 4) other/none. Months following an increase in
herapy level were flagged as “exacerbation” and months fol-
owing a decrease in therapy levelwere flagged as “remission.”
f a beneficiary exhibited consistent patterns of service use
ver time, allmonthswere flagged as “plateau/stable disease.”
Progressive caseswere restricted to pre-existing caseswith
t least 12 months of recorded MS history and one of the fol-
owing: 1) at least 10 of the last 12 months at the exacerbation
evel; 2) the last 12 months at the plateau/stable level with a
nal therapy type of nursing home, home health, or selected
ehabilitation therapy/DME; or 3) a 2005 or 2006 JENAssociates
railty index of 7 or above. (This score is based on 13 medical 9ondition groups significantly related to concurrent or future
eed for long-term care services [16,17]. Each condition group
agged in a year’s Medicare claims increases the patient’s
railty score by 1 point for that year, and each point increase
enotes a proportional increase in the risk of future hospital-
zation, long-term care use, and death.)
Relapsing-remitting cases included all other pre-existing
ases with at least 12 months of recorded MS history and a
nal value of exacerbation, remission, or plateau/stable (with-
ut therapy support). Patients with less than 12 months MS
istory were classified as unknown disease level.
Multivariate regression models were created to explore
actors associatedwith direct costs separately in the prevalent
RMS and progressive MS cohorts. Descriptive and univariate
nalyses were performed on the prevalence and the cost rela-
ionships of covariates considered to be related to medical
tilization and/orMS in order to determine the list of covariates
onsidered inmodeling. These covariates included demograph-
cs, eligibility characteristics, and 2005 comorbid chronic disease
nd mental health variables. Additionally, utilization from the
ast quarter of 2005 was used to create baseline measures of
ospitalization, general practitioner, outpatient clinic, emer-
ency room, mental health, specialist, and therapy encounters.
eath is the primary reason for loss of follow-up in 2006 and is
lso considered as a model covariate. The regression models
ere developed using a forward, stepwise selection of covari-
tes, requiring P  0.05 for model entry and final inclusion to
redict total 2006Medicare expenditures. For the RRMSmodel, a
aseline indicator for relapse during the last quarter of 2005was
lso included. Model testing revealed that a square root
ransformation of total Medicare expenditures was appro-
riate for the data. Given the difficulty of interpreting
quare root–transformed results, the models that produced
he results use normal/untransformed dollars, but are
ased on the covariates obtained from the square root–
ransformed models. This untransformed methodology
roduced results with magnitude and direction of all model
ovariates comparable to those observed in themodels with
he square root transformation.
esults
atient characteristics
here were estimated to be 100,880 MS cases in 2006 selected
or these analyses, of which 34.4% were prevalent cases with
rogressive MS and 65.6% were prevalent cases with RRMS
Table 1). The proportion of females across the 2 groups varied
inimally from 73% to 74%. The mean ages varied more: 61
ears for the progressive cohort to 56 years for RRMS. Whites
onstituted the largest racial group (85%, 87%). A majority of
revalent cases were originally eligible for Medicare on the
asis of disability rather than age. Loss of follow-up in 2006
asminimal, and themeanmonths of follow-up in 2006 were
1.4 for the progressive cohort and 11.8 for the RRMS cohort.
eath was the primary reason for loss of follow-up and was
reatest in the progressive cohort, which had a death rate of
.6% as compared to a death rate of 1.2% in the RRMS cohort.
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64 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 1 - 6 9The rates of the most common comorbid conditions for
revalent progressive MS and prevalent RRMS cases, respec-
ively, were depression (51.7%, 24.4%), ischemic heart disease
31.1%, 12.1%), diabetes (28.6%, 13.3%), chronic obstructive
ulmonary disease (28.0%, 12.9%%), cardiovascular disease
24.3%, 6.5%), and arthritis (22.5%, 15.5%). The death rates in
006 were 9.1% for progressive MS patients and 1.2% for RRMS
atients (Table 1).
lassification
test was performed on pre-existing cases to assess the sta-
Table 1 – Demographics classified by MS type.
2006 Attributes Pre-existing cases type*
Progressive MS RRMS
N (%) 34,680 (29.7%) 66,200 (56.7%)
Demographics
Gender
Female 72.9% 74.1%
Age, end of 2006, years
Age 65 60.2% 73.4%
Age 65 39.8% 26.6%
Age, mean (SD), median 60.9 (13.0), 60 56.3 (11.9), 56
Race
White 85.4% 86.5%
Black 11.7% 10.7%
Other/unknown 2.9% 2.8%
County setting
Urban 78.0% 74.0%
Eligibility Characteristics
Original Medicare entitlement
Old age 16.7% 13.7%
Disability (and/or ESRD) 83.3% 86.3%
Current entitlement
Old age 39.7% 26.0%
Disability (and/or ESRD) 60.3% 74.0%
Eligibility months relative to index
Pre-index eligible months, mean
(SD), median
33.3 (7.0), 36 31.0 (9.2), 36
Post-index eligible months,
mean (SD), median
11.4 (2.0), 12 11.8 (1.3), 12
Comorbid chronic diseases
Alzheimer’s/dementia 19.2% 3.0%
Arthritis 22.5% 15.5%
Diabetes 28.6% 13.3%
Ischemic heart disease 31.1% 12.1%
Congestive heart failure 15.7% 3.2%
COPD 28.0% 12.9%
Cardiovascular disease 24.3% 6.5%
Parkinson’s 2.4% 0.5%
Schizophrenia 2.2% 0.5%
Depression 51.7% 24.4%
Psychosis 9.1% 1.1%
Alcohol/substance abuse 3.4% 1.0%
Death in 2006 9.1% 1.2%
COPD, chronic obstructive pulmonary disease; ESRD, end-stage
renal disease; RRMS, relapsing-remitting MS; SD, standard devi-
ation.
* Less than 1% of the pre-existing cases had insufficient data for
disease classification; these cases are not profiled separately.ility of the disease level classification. For cases with ade- cuate history, the disease level was calculated at the end of
005 and compared with the disease level classification at the
nd of 2006. There are two noteworthy results: 1) Almost 85%
aintained their classification of progressive disease across
he 2 years, which indicates good stability in the assignment
lgorithm. The approximately 15% reversion rate to RR status
rom progressive can be considered an indication of a type 1
lassification error. 2) The 12.7% promotion rate from RRMS to
rogressive MS across the 2 years represents a combination of
atural disease exacerbation and a potential classification er-
or.
edicare expenditures and utilization
he mean all-cause Medicare expenditures (not including
elf-administered outpatient medication expenses) per per-
on-year forMS in 2006were $23,630 for prevalent progressive
S patients and $5887 for prevalent RRMS patients (Table 2).
eanMS-specific costs in 2006 were $4521 and $1485 for prev-
lent progressive MS and prevalent RRMS, respectively. Prev-
lent progressive MS cases had substantially higher attribut-
ble inpatient acute care, skilled nursing facility, and home
ealth care expenditures than those with prevalent RRMS.
he greatest costs by category, in descending order byMS case
ype (prevalent progressiveMS, prevalent RRMS)were, respec-
ively, inpatient acute care ($7497, $1263), skilled nursing fa-
ility ($3274, $205), home health care ($3159, $554), physician
$2578, $1114), and inpatient chronic care ($1886, $425). Prev-
lent progressive MS patients had higher all-cause utilization
ates than patients with prevalent RRMS (per 1,000) in-home
ealth aide units (17,689 vs. 1272), home health skilled units
4269 vs. 531), skilled nursing facility days (12,769 vs. 728), spe-
ialist encounters (9281 vs. 7129), inpatient acute days (7007
s. 980), therapy encounters (3509 vs. 1395), and general prac-
itioner encounters (6937 vs. 4061). At the end of the time pe-
iod of this study, the percentage of MS patients in 2006 that
tilized follow-up therapy by MS case type of progressive MS
nd RRMS cases, respectively, were nursing home (39.4%,
.3%), home health care (22.8%, 3.2%), and supportive therapy/
ME (19.6%, 10.5%).
stimated unit costs
egression analyseswere conducted to estimate the unit costs
not including self-administered medications) per year for
vents, adjusted for differences in patient demographics and
omorbidity for the progressive MS and RRMS populations
Table 3). For patients with RRMS, relapse-related hospitaliza-
ions and nonrelapse-related hospitalizations were the costli-
stMS-specific events, adding $13,265 and $10,435 toMedicare
osts, respectively. Need for home health care and skilled
ursing facilities added $9402 and $5099 per annum, respec-
ively. In patients with progressive MS, hospitalization in-
urred Medicare costs of $23,682 (non-MS) or $16,738 (MS-re-
ated). The need for home health care was the third most
ostly ($19,950 per annum).
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65V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 1 - 6 9xpenditures and utilization by RRMS health state
he health states in patients with RRMS were labeled relaps-
ng, remitting, and stable. Among the RRMS Medicare pa-
ients, the greatest MS-specific health resource utilization oc-
urred for the relapse patients (Table 4). Supportive therapy
tilizationwas 100% for relapsing patients, 12.6% for remitting
atients, and 3.4% for stable patients. Another frequently used
esource was selected rehabilitation therapy/DME for which
Table 2 – Annual utilization rates and annual direct medic
2006 Attributes
N (%)
MS supportive therapy, ranked
Nursing home
Home health
Selected rehabilitation therapy/DME
Any supportive therapy
End of follow-up therapy
Nursing home (2006 death rate)
Home health
Supportive therapy/DME
None/other
Use months, percent of eligibility months
MS diagnosis months
MS supportive therapy months
Nursing home
Home health
Selected rehabilitation therapy/DME
Any supportive therapy
MS-specific expenditures in 2006, mean (SD), median
All-cause expenditures in 2006, mean (SD), median
Ambulance/transport
Home health
Hospice
Inpatient acute
Inpatient chronic
Outpatient
Practitioner
Physician
Skilled nursing facility
Supplies/DME
Testing
Total expenditures
Annual utilization rate (per 1000 patient-years), mean (SD), median
Inpatient acute episodes
General practitioner encounters
Outpatient clinic encounters
Outpatient emergency room encounters
Specialist encounters
Rehabilitation therapy encounters
Inpatient acute days
Inpatient chronic days
Inpatient rehabilitation days
Skilled nursing facility days
Home health aide units
Home health skilled units
Home health therapy units
DME, durable medical equipment; RRMS, relapsing-remitting MS; SD
* Profile is based on 2006 eligible months, excluding the last eligible m
for the profile.he mean use was 70.0%, 5.9%, and 0.3%, respectively. lMean Medicare expenditures (not including self-adminis-
ered medications) per person-month in 2006 were $1418 for
elapsing patients, $608 for remitting patients, and $331 for
table patients. The greatest specific mean costs per month,
y relapsing, remitting, and stable patients were, respectively,
ome health care ($313, $46, and $13), inpatient acute care
$272, $132, and $75), physician visits ($154, $114, and $78), and
upplies/DME ($137, $65, and $26). The greatest utilization
ates for Medicare, as reported per 1000 patient-years by re-
sts classified by MS type.
Pre-existing case type*
Progressive MS RRMS
34,680 (29.7) 66,200 (56.7)
42.6% 2.0%
30.9% 6.5%
32.0% 21.8%
88.1% 26.0%
39.4% (14%) 1.3% (4.8%)
22.8% 3.2%
19.6% 10.5%
18.2% 85.0%
68.0% 41.4%
36.0% 0.8%
22.0% 2.4%
20.0% 8.1%
79.0% 11.3%
$4521 ($8138), $977 $1485 ($4023), $276
$548 ($1075), $121 $61 ($276), $0
$3159 ($5510), $0 $554 ($1928), $0
$808 ($4951), $0 $171 ($2267), $0
$7497 ($14,539), $0 $1263 ($4471), $0
$1886 ($8226), $0 $425 ($3325), $0
$359 ($931), $79 $217 ($688), $0
$405 ($1061), $74 $213 ($552), $0
$2578 ($2976), $1,648 $1114 ($1736), $573
$3274 ($7564), $0 $205 ($2045), $0
$1463 ($2955), $282 $533 ($1759), $0
$981 ($1084), $619 $644 ($819), $325
$23,630 ($27,961), $13,936 $5887 ($10,088), $2206
900 (1258), 0 194 (535), 0
6937 (7386), 5000 4061 (6334), 2000
1192 (3194), 0 1105 (3109), 0
730 (1514), 0 399 (1316), 0
9281 (9688), 7000 7129 (8216), 5000
3509 (7257), 1000 1395 (4041), 0
7007 (13,801), 0 980 (3220), 0
732 (6033), 0 71 (1813), 0
950 (5463), 0 281 (2296), 0
12,769 (34,352), 0 728 (7352), 0
17,689 (88,915), 0 1272 (13,857), 0
4269 (22,957), 0 531 (3028), 0
1801 (6893), 0 463 (2591), 0
dard deviation.
in the year. There were 240 RRMS cases lacking sufficient 2006 dataal co
, stan
onthapsing, remitting, and stable patients were, respectively, spe-
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66 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 1 - 6 9ialist physician encounters (854, 685, and 547), home health
ide units (697, 123, and 30), therapy encounters (661, 104, and
3), skilled nursing facility days (466, 35, and 21), general prac-
itioner encounters (465, 375, and 318), home health skilled
nits (327, 35, and 13), and home health therapy units (290, 36,
nd 9) (Table 4). The added per patient per year cost to Medi-
are of relapse-remitting periods was $1878 above the costs of
S stability (derived from the costs and stage duration statis-
ics in Table 4).
iscussion
o our knowledge, this is the first study that used health care
ayer data to compare the health utilization and costs of the
elapsing-remitting and progressive forms of MS. It is also the
rst study to report the cost of care in each relevant health
ategory within the RRMS population. This study and that of
rescott et al. [3] both report substantial nonpharmacy health
ervice use. Whereas Prescott combined all MS cases, our
tudy examined utilization by MS stage and found that there
as substantially greater utilization for progressive MS dis-
ase than for RRMS. The use of our classification model per-
its thesemeasures using the large claims databases that are
he best source of payment data.
Whetten-Goldstein et al. [13] is one US study that also
ttempted to break down costs according to MS disease
Table 3 – Multivariate regression results of direct medical c
Variable DF
RRMS model (adjusted R2  0.47)
Intercept 1
2005 Ischemic heart disease 1
Baseline general practitioner encounters 1
Baseline outpatient clinic encounters 1
Baseline emergency room encounters 1
Baseline specialist encounters 1
2006 Non-MS inpatient admission 1
2006 MS relapse-related inpatient admission 1
2006 MS nonrelapse inpatient admission 1
2006 Nursing home 1
2006 Skilled nursing facility 1
2006 Home health 1
2006 Supportive therapy 1
2006 Death 1
Progressive MS model (adjusted R2  0.46)
Intercept 1
Age 80 1
Black race/ethnicity 1
West region 1
Baseline inpatient status 1
Baseline specialist encounters 1
2006 MS inpatient admission 1
2006 Non-MS inpatient admission 1
2006 Nursing home 1
2006 Skilled nursing facility 1
2006 Home health 1
2006 Supportive therapy 1
2006 Death 1
RRMS, relapsing-remitting MS.tage. Like our study, it found that the annual cost for dhronic progressive MS far exceeds the relapsing-remitting
tage of MS. TheWhetten-Goldstein results, however, are 16
ears old, and they rely on responses from a 600-person
elephone survey. It can be difficult for MS patients to report
heir disease status given the lack of clear distinction be-
ween the different stages [6,18].
The expenditures for which progressive cases substan-
ially exceeded RRMS cases were inpatient acute care,
killed nursing facility, and home health care. However, it is
mportant to note that the only prescription drugs covered
nder Medicare prior to 2006 were ones that cannot be ad-
inistered in an ambulatory setting. Our study did not in-
lude outpatient pharmacy claims from the Medicare Part D
enefit. Previous studies that included all prescription med-
cations have concluded that medications constitute the
argest proportion of direct medical costs. Thus, direct med-
cal costs that include prescription medications would in-
rease the total cost well above our estimates. Previous
tudies reported mean annual direct medical costs to be
12,879 in 2004 [3], $29,634 in 2004 [11], and $9500 to $10,200
n 1996 to 2001 [4].
O’Brien et al. [19] calculated that in 2002, the directmedical
osts of an MS relapse ranged from $243 for a mild incident to
12,870 for a severe one. Much of the extra cost was due to
ospitalization. This study partly relied on payer data that did
ot indicate patients’ disease stage. The study also could not
ake into account the ongoing costs of repeated or continuing
.
stimate Error T value P value
$1306 396.11 3.30 0.0010
$850 422.68 2.01 0.0444
$187 67.30 2.78 0.0055
$385 98.81 3.90 .0001
$1711 336.70 5.08 .0001
$607 54.42 11.15 .0001
$11,227 424.38 26.46 .0001
$13,265 1773.02 7.48 .0001
$10,435 731.80 14.26 .0001
$10,983 1075.68 10.21 .0001
$5099 1020.84 4.99 .0001
$9402 540.54 17.39 .0001
$3126 323.56 9.66 .0001
$6358 1191.57 5.34 .0001
$9117 1467.94 6.21 .0001
$5317 1814.57 2.93 0.0034
$4277 1580.59 2.71 0.0069
$3053 1419.31 2.15 0.0316
$3206 1365.52 2.35 0.0190
$1454 193.19 7.53 .0001
$16,738 1939.85 8.63 .0001
$23,682 1092.39 21.68 .0001
$9336 1469.89 6.35 .0001
$7109 1390.53 5.11 .0001
$19,950 1196.64 16.67 .0001
$6544 1202.78 5.44 .0001
$3788 1762.74 2.15 0.0318osts
E

isease exacerbation.
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67V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 1 - 6 9Our study found that RRMS patients with relapse had far
ighermeanmonthly total expenditures ($1418) than patients
n either the remitting or stable health states ($608 and $331,
espectively). Patients with progressive MS had mean costs in
006 approximately fourfold higher than RRMS patients
$23,630 vs. $5887). The higher expenditures associated with
elapse in the RRMS population were driven by inpatient ad-
issions and uses of skilled nursing facilities, home health
ncounters, and DME compared to stable RRMS patients. The
ost of a relapse, however, should also include the higher
osts per month in the remitting state of health, which ap-
eared to last an average of 3.05 months for a total length of
elapse and recovery of 4 months. The higher monthly cost in
he remitting state ($608) was almost double the mean
onthly cost in the stable state ($331). These results begin to
rame the economic benefit of avoiding relapses by keeping
RMS patients in a stable health state.
This study also documents the high rates of comorbidity in
Table 4 – MS-specific monthly utilization and expenditure
Eligibility months,* sum
Eligibility months,* mean (SD), median 0
MS supportive therapy, % eligibility months
Nursing home
Home health
Selected rehabilitation therapy/DME
Any supportive therapy
Medicare expenditures per month, mean (SD), median
Ambulance/transport
Home health $
Hospice
Inpatient acute $
Inpatient chronic $
Outpatient
Practitioner
Physician $
Skilled nursing facility $
Supplies/DME $
Testing
Total Medicare expenditures $1,
Monthly Medicare utilization rate per 1000
patient-months, mean (SD), median
Inpatient acute episodes
General practitioner encounters
Outpatient clinic encounters
Outpatient emergency room encounters
Specialist physician encounters
Rehabilitation encounters
Inpatient acute days
Inpatient chronic days
Inpatient rehab days
Skilled nursing facility days
Home health aide units
Home health skilled units
Home health therapy units
DME, durable medical equipment; RRMS, relapsing-remitting MS; SD
* Profile is based on 2006 eligible months, excluding the last eligible m
for the profile.he MS population reimbursed by Medicare. MS comorbidities oeldom appear in other US cost-of-illness studies. Epidemio-
ogic studies in the United States and elsewhere have noted
uch conditions as depression, hypercholesterolemia, periph-
ral vascular disease, hypertension, arthritis, systemic lupus
rythematosus, urinary tract infection, and pneumonia or in-
uenza [20–24]. The interaction between MS and comorbidi-
ies can be bidirectional: A recent report notes that vascular
omorbidity accelerates MS progression [25].
A large number of the MS cases in our study had concom-
tant chronic diseases including depression, ischemic heart
isease, diabetes, chronic obstructive pulmonary disease, car-
iovascular disease, and arthritis. This was true for both MS
ypes but especially for pre-existing progressive disease pa-
ients. We estimated that the meanMedicare expenditure per
erson-year for MS in 2006 (not including self-administered
edications) was $23,630 for progressive patients and $5887
or pre-existing RRMS patients, but expenditures coded for
laimswith aMS primary diagnosis were only about a fraction
RMS Status.
Monthly RRMS disease status
psing Remitting Stable
,880 201,040 448,980
.06), 0 3.05 (4.45), 0 6.81 (5.13), 11
.0% 0.0% 0.1%
1.0% 1.1% 0.3%
0.0% 5.9% 0.3%
0.0% 12.6% 3.4%
125), $0 $7 ($65), $0 $3 ($43), $0
704), $0 $46 ($292), $0 $13 ($155), $0
237), $0 $39 ($391), $0 $2 ($89), $0
1618), $0 $132 ($1146), $0 $75 ($961), $0
1461), $0 $44 ($737), $0 $19 ($498), $0
100), $0 $22 ($110), $0 $16 ($131), $0
203), $0 $18 ($84), $0 $8 ($56), $0
352), $46 $114 ($324), $28 $78 ($275), $0
972), $0 $10 ($240), $0 $7 ($212), $0
845), $0 $65 ($569), $0 $26 ($340), $0
209), $0 $63 ($204), $0 $50 ($181), $0
3132), $469 $608 ($1932), $93 $331 ($1522), $28
92), 0 22 (150), 0 12 (111), 0
044), 0 375 (762), 0 318 (719), 0
79), 0 111 (425), 0 82 (363), 0
33), 0 42 (257), 0 28 (186), 0
390), 0 685 (1220), 0 547 (971), 0
607), 0 104 (541), 0 53 (396), 0
147), 0 99 (759), 0 60 (642), 0
017), 0 0 (0), 0 3 (232), 0
71), 0 34 (686), 0 13 (402), 0
370), 0 35 (872), 0 21 (671), 0
305), 0 123 (1683), 0 30 (1144), 0
629), 0 35 (491), 0 13 (258), 0
842), 0 36 (632), 0 9 (262), 0
dard deviation.
in the year. There were 240 RRMS cases lacking sufficient 2006 databy R
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68 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 1 - 6 99.1% of all-cause expenditure for progressive MS and 25.2%
or RRMS.
These results demonstrate that the overall cost of care of
hese patients is greatly affected by comorbid status. This be-
omes important formodeling or directlymeasuring potential
ost offsets from new MS therapies. A drug that improves MS
ymptom control must also reduce comorbid conditions. Oth-
rwise, the cost offsets of amelioratingMSwill be smaller than
redicted when modeling direct medical costs as if they were
ll due to MS. These study results help clarify this issue, espe-
ially from a viewpoint of the large and clinically advanced
opulation reimbursed by US Medicare.
The Medicare population includes individuals who are ei-
her of working age but completely disabled or are elderly pa-
ientswith longhistories ofMS. Therefore,MedicareMSpatients
isproportionately suffer from the progressive form of the dis-
ase, either primary or secondary. The Medicare program
rom 2003 to 2006 covered hospital stays (Part A) and ambula-
ory costs resulting from physician visits, rehabilitation, post
cute care, and prescription drugs that cannot be adminis-
ered in an ambulatory setting. Approximately 39% of the
edicare MS patients with progressive disease in our study
ere in a nursing homepart or all of 2006, but thatwas true for
nly 1% of RRMS patients. By contrast, Kobelt [12] found only
%of allMS patientswere in a nursing homepart or all of 2004.
imitations
here are several limitations to this study. First, its specific
se of a population reimbursed by Medicare may not allow all
rends and relationships to be generalized to younger and less
isabled MS populations. These populations would be more
ppropriately analyzed in commercial reimbursement data-
ases that have previously been published. The costs in this
tudy do not apply outside of the United States. This study,
ikemany other burden of illness analyses, was not societal in
erspective, so it ignored indirect costs resulting from circum-
tances such as early retirement, lost income, lost work time,
r informal unpaid care, which constitute a substantial pro-
ortion of economic burden [11,12]. This study did not capture
he full extent of direct medical costs because Medicare parts
and B do not reimburse drugs that can be administered in an
mbulatory setting; other researchers have found drug costs
o be substantial [3,4,11].
These last two limitations could be overcome by use of
odeling techniques to support a more societal perspective
ithin the United States. The introduction of the Medicare
art D benefit in 2006 opens the opportunity to expand the
nalysis to include the costs of outpatient, self-administered
rug therapies as a function of MS stage.
The method used to classify patients into either MS type
as not been used previously, to our knowledge, and is not
onsidered to be validated. Validation could be done directly
hrough a costly and logistically challenging chart review,
ooking for evidence of relapse events or scores from use of
alidated severity scales (e.g., EDSS). Indirect validation could
e done through replications of application in other popula-
ion data sets.Among patients classified with progressive disease at the
nd of 2005, 15.3% were classified with RRMS in 2006. This
attern represents the algorithm’s classification error for pro-
ressive cases.
onclusions
he results of this study identify the high costs borne byMedi-
are for the reimbursement of qualified patients with MS. A
arge proportion of total direct medical costs were found to be
ssociated with comorbid conditions. Differential costs of pa-
ients with progressive MS versus RRMS were demonstrated,
lbeit with a classification method that is not fully validated.
his objective MS classification method nonetheless repre-
ents a breakthrough in studying MS cost of illness. The study
eported here shows that classifying MS patients according to
iagnostic stage is feasible and yields useful information. The
otential cost advantage to Medicare of avoiding relapse and
eeping the patientwith RRMS fromadvancing to the progres-
ive stage is suggested by these results, allowingmore specific
ata for future modeling of treatments.
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